With an ever changing technological environment and an unstable economic scenario, many scientific studies are being conducted which are leading to the discovery of new coagulation factors, proteins and plasma concentrates used for treating chronic diseases and medical conditions. The market for hemophilia products has shown continuous growth in the past years growing at a CAGR of around 8.96% during 2006-11 and is projected to expand steadily in the years to come.
The occurrence rate of bleeding disorders such as hemophilia is increasing, calling for an increased usage of blood plasma products. The male population of the world is rising and males are the ones who are worst affected by hemophilia as they carry only one X chromosome. Females are only the carriers of this disease. Furthermore, the increasing expenditure is also responsible for higher utilization of recombinant and plasma derived coagulation factors. The existing treatments for hemophilia treatment comprise of blood plasma derivatives and recombinant factors.
The leading players in the hemophilia treatment market include: Baxter, Grifols, Pfizer and Novo Nordisk, among others, competing mainly on the basis of product pricing and performance, supply of the products, and continuous offering of new and innovative protein and blood plasma derivatives. Apart from this, the presence of several players operating at domestic level, emergence of new players, and agreements with government agencies, academic and research institutions make the therapeutic landscape of hemophilia market fiercely competitive.
The key trends in the hemophilia treatment market are the increasing inclination towards prophylaxis, limiting the use of central venous access device for prophylactic treatment, development of long-acting Factor VIII and IX, deep penetration of rFVIII products within the emerging markets. The recent developments in the respective field include gene therapy for treating hemophilia B, half life extension of the recombinant coagulation factors, development of 4-factor PCC for reversal of vitamin K antagonist anticoagulant therapy along with recent approval of ADVATE in China apart from other clinical trials on run.
The major factors driving the growth of the industry are the increasing number of new patients registering themselves for treatment at the hospitals and other healthcare institutions, growing male population, rising expenditure on healthcare globally, and the increased life expectancy for hemophilia patients.
Although this industry has been witnessing an aggressive growth with latest technological advancements, still there are factors like antibody neutralization and lack of diagnostic facilities leading to improper or late detection of the disease, which are posing acute challenges in front of every other person falling within the realm of this therapeutic field.
The report provides an analysis of the global hemophilia treatment market. It also discusses the major trends, growth drivers and potential markets. The report presents the competitive structure of the industry and profiles major players in the market with a discussion of their key business strategies.
By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
Published: June 2012 No. of Pages: 47
Price: Single User: US $ 800 Corporate User: US $ 1600
Table Of contents
1. Hemophilia: An Overview
2. Market Overview
2.1 Global Heamophilia Market
Market Value
No. of Patients
2.2 Global Hemophilia Market by Type
2.2.1 Hemophilia A
Market Characteristics
Market Size
Key Products
2.2.2 Hemophilia B
Market Characteristics
Market Size
Key Products
2.2.3 Hemophilia with Inhibitor
2.3 Global Hemophilia Therapeutics Market by Region
2.3.1 Australia
Market Overview
Volume of Patients
Demand of Plasma Derived Factor IX
Demand of Recombinant Factor IX
2.3.2 The US
Market Overview
Plasma Derived FVIII Market Share
Distribution Growth of rFVIII products
New Patient Registrations
3. Hemophilia Market Dynamics
3.1 Key Trends
3.1.1 Inclination towards Prophylaxis
3.1.2 Abated Use of Central Venous Access Device for Prophylactic
3.1.3 Long-Acting Factor VIII and IX Development
3.1.4 Growing Penetration of rFVIII Products in Emerging Markets – Opportunity for Manufacturers
3.2 Industry Developments
3.2.1 Innovative Gene Therapy for Treating Heamophilia B
3.2.2 Extended Half Life of the Recombinant Coagulation Factors
3.2.3 Development of 4-factor PCC for Reversal of Vitamin K Antagonist Anticoagulant Therapy
3.2.4 Approval of ADVATE in China
3.2.5 Baxter’s Phase I Clinical Trial of Treatment for Hemophilia A
3.3 Growth Drivers
3.3.1 Increasing New Patient Registration
3.3.2 Rising Male Population
3.3.3 Increasing Expenditure on Healthcare
3.3.4 Increasing Life Expectancy for Hemophilia Patients
3.4 Challenges
3.4.1 Risk of Antibody Neutralization
3.4.2 Misdiagnosis of the Disease
4. Hemophilia Market - Competitive Scenario
Competition in Hemophilia A Market
Competition in Hemophilia B Market
5. Company Profiles
5.1 Novo Nordisk
Business Description
Key Financials
Business Strategies
Focus on Hormone Therapy
Establish Leadership Position
5.2 Baxter International
Business Description
Key Financials
Business Strategies
Focus on Investment in Research & Development
Achieving Growth through Sustainable Development
5.3 Grifols
Business Description
Key Financials
Business Strategies
Expansion in Other Geographic Regions
Growth through Mergers & Acquisitions
5.4 Pfizer, Inc.
Business Description
Key Financials
Business Strategies
Focus on Growth
Strategic Acquisitions
6. Market Outlook
6.1 Market Forecast
6.2 Forecast Methodology
6.2.1 Dependent and Independent Variables
6.2.2 Correlation Analysis
6.2.3 Regression Analysis
List of Tables
Market Characteristics for Hemophilia A Treatments (2010)
Revenues of Key Products in Hemophilia A Treatment Market (2010 & 2016F)
Products for Hemophilia A Treatment
Market Characteristics for Hemophilia B Treatments (2010)
Revenues of Key products in Hemophilia B Treatment Market (2010 & 2016F)
Products for Treatment of Hemophilia B
New Patient Registrations in the US Bleeding Disorders Market (1998-2013E)
Growth in the New Patient Registrations in the US (2009-2013E)
Treatment of Hemophilia B Patients registered at CDC, the US (December 2011)
Long Acting FIX & FVIII under Late-Stage Development
% Conversion to Recombinant Factor VIII Products in Selected Countries (2010)
Reduction in the Number of Injections required by using Half-Life Extension
Extended Half Life rFVIII Agents
Extended Half Life rFIX Agents
New Patient Registrations in Worldwide Bleeding Disorders Market (2008-2013E)
Viral Infection Rates among Hemophiliacs (by Disease Type)
Competition in Hemophilia A Market – Emerging Products
Competition in Hemophilia B Market – Emerging Products
Dependent & Independent Variables (2006-2011)
Correlation Matrix
Model Summary – Coefficient of Determination
Regression Coefficients Output"
List of Charts
Number of Patients by Hemophilia Type (2010)
Global Hemophilia Treatment Market Revenues (2006-2011)
Global Hemophilia A Market Size (2010-2016F)
Global Recombinant FVIII Market Revenues (2005-2011)
Global Hemophilia B Market Size (2010-2016F)
Global Recombinant FIX Market Size (2006-2011)
Annual Global Sales of NovoSeven (2007-2011)
Quarterly Sales of Novoseven (Q109-Q112)
Major Clotting Disorders, by Volume of Patients Requiring Treatment (2010)
Demand of Plasma Derived Factor IX in Australia (2007-2010)
Demand of Recombinant Factor IX in Australia (2007-2010)
The US Plasma Derived FVIII Market Share by Companies (2010)
Distribution Growth of rFVIII products in the US (Nov 2010-Nov 2011)
Use of Prophylaxis in Different Age Brackets (2011)
Global Male Population (2005-2014F)
Novo Nordisk Revenue Share by Business Segments (2011)
Novo Nordisk Revenues & Net Income (2008-2011)
Baxter’s Revenue by Business Segments (2011)
Baxter’s Revenues and Net Income (2008-2011)
Grifols Revenue Share by Business Segments (2011)
Grifols Revenues & Profits (2008-2011)
Pfizer’s Revenue Share by Business Segments (2011)
Pfizer’s Revenues & Net Income (2008-2011)
Global Hemophilia Treatment Market Forecast (2010-2014F)
1. Hemophilia: An Overview
2. Market Overview
2.1 Global Heamophilia Market
Market Value
No. of Patients
2.2 Global Hemophilia Market by Type
2.2.1 Hemophilia A
Market Characteristics
Market Size
Key Products
2.2.2 Hemophilia B
Market Characteristics
Market Size
Key Products
2.2.3 Hemophilia with Inhibitor
2.3 Global Hemophilia Therapeutics Market by Region
2.3.1 Australia
Market Overview
Volume of Patients
Demand of Plasma Derived Factor IX
Demand of Recombinant Factor IX
2.3.2 The US
Market Overview
Plasma Derived FVIII Market Share
Distribution Growth of rFVIII products
New Patient Registrations
3. Hemophilia Market Dynamics
3.1 Key Trends
3.1.1 Inclination towards Prophylaxis
3.1.2 Abated Use of Central Venous Access Device for Prophylactic
3.1.3 Long-Acting Factor VIII and IX Development
3.1.4 Growing Penetration of rFVIII Products in Emerging Markets – Opportunity for Manufacturers
3.2 Industry Developments
3.2.1 Innovative Gene Therapy for Treating Heamophilia B
3.2.2 Extended Half Life of the Recombinant Coagulation Factors
3.2.3 Development of 4-factor PCC for Reversal of Vitamin K Antagonist Anticoagulant Therapy
3.2.4 Approval of ADVATE in China
3.2.5 Baxter’s Phase I Clinical Trial of Treatment for Hemophilia A
3.3 Growth Drivers
3.3.1 Increasing New Patient Registration
3.3.2 Rising Male Population
3.3.3 Increasing Expenditure on Healthcare
3.3.4 Increasing Life Expectancy for Hemophilia Patients
3.4 Challenges
3.4.1 Risk of Antibody Neutralization
3.4.2 Misdiagnosis of the Disease
4. Hemophilia Market - Competitive Scenario
Competition in Hemophilia A Market
Competition in Hemophilia B Market
5. Company Profiles
5.1 Novo Nordisk
Business Description
Key Financials
Business Strategies
Focus on Hormone Therapy
Establish Leadership Position
5.2 Baxter International
Business Description
Key Financials
Business Strategies
Focus on Investment in Research & Development
Achieving Growth through Sustainable Development
5.3 Grifols
Business Description
Key Financials
Business Strategies
Expansion in Other Geographic Regions
Growth through Mergers & Acquisitions
5.4 Pfizer, Inc.
Business Description
Key Financials
Business Strategies
Focus on Growth
Strategic Acquisitions
6. Market Outlook
6.1 Market Forecast
6.2 Forecast Methodology
6.2.1 Dependent and Independent Variables
6.2.2 Correlation Analysis
6.2.3 Regression Analysis
List of Tables
Market Characteristics for Hemophilia A Treatments (2010)
Revenues of Key Products in Hemophilia A Treatment Market (2010 & 2016F)
Products for Hemophilia A Treatment
Market Characteristics for Hemophilia B Treatments (2010)
Revenues of Key products in Hemophilia B Treatment Market (2010 & 2016F)
Products for Treatment of Hemophilia B
New Patient Registrations in the US Bleeding Disorders Market (1998-2013E)
Growth in the New Patient Registrations in the US (2009-2013E)
Treatment of Hemophilia B Patients registered at CDC, the US (December 2011)
Long Acting FIX & FVIII under Late-Stage Development
% Conversion to Recombinant Factor VIII Products in Selected Countries (2010)
Reduction in the Number of Injections required by using Half-Life Extension
Extended Half Life rFVIII Agents
Extended Half Life rFIX Agents
New Patient Registrations in Worldwide Bleeding Disorders Market (2008-2013E)
Viral Infection Rates among Hemophiliacs (by Disease Type)
Competition in Hemophilia A Market – Emerging Products
Competition in Hemophilia B Market – Emerging Products
Dependent & Independent Variables (2006-2011)
Correlation Matrix
Model Summary – Coefficient of Determination
Regression Coefficients Output"
List of Charts
Number of Patients by Hemophilia Type (2010)
Global Hemophilia Treatment Market Revenues (2006-2011)
Global Hemophilia A Market Size (2010-2016F)
Global Recombinant FVIII Market Revenues (2005-2011)
Global Hemophilia B Market Size (2010-2016F)
Global Recombinant FIX Market Size (2006-2011)
Annual Global Sales of NovoSeven (2007-2011)
Quarterly Sales of Novoseven (Q109-Q112)
Major Clotting Disorders, by Volume of Patients Requiring Treatment (2010)
Demand of Plasma Derived Factor IX in Australia (2007-2010)
Demand of Recombinant Factor IX in Australia (2007-2010)
The US Plasma Derived FVIII Market Share by Companies (2010)
Distribution Growth of rFVIII products in the US (Nov 2010-Nov 2011)
Use of Prophylaxis in Different Age Brackets (2011)
Global Male Population (2005-2014F)
Novo Nordisk Revenue Share by Business Segments (2011)
Novo Nordisk Revenues & Net Income (2008-2011)
Baxter’s Revenue by Business Segments (2011)
Baxter’s Revenues and Net Income (2008-2011)
Grifols Revenue Share by Business Segments (2011)
Grifols Revenues & Profits (2008-2011)
Pfizer’s Revenue Share by Business Segments (2011)
Pfizer’s Revenues & Net Income (2008-2011)
Global Hemophilia Treatment Market Forecast (2010-2014F)
No comments:
Post a Comment